Navigation Links
CRISPR Cas9 Genome Editing Market Worth $5.3 Billion by 2025

CRISPR | Cas9 Market and Patent Landscape Report by Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal and disease model), by Products (editing tools, cell lines, animal models and plant breeding products), by Technology (drug compound and target screening, and agriculture and industrial use), by Patent Activities (patent categories and classification, leading patent players, technical analysis of patent landscape, patent licensing and litigation) – Global Forecast, 2025.

The global markets for CRISPR-Cas9 genome editing were estimated at $1.22 billion in 2017 and it is expected to reach $5.3 billion by 2025 growing at a CAGR of 20.19 percent.

This report focuses on the CRISPR-Cas9 genome editing tools including its technology, market, and patent landscape. The report forecasts the sizes and trends of the global market as well as its sub-segments for the period 2018 to 2025. The report focuses on critical market segments to identify the key market and technology trends. Market driving factors and constraints have been considered to estimate global CRISPR-Cas9 market potential.

Patent trends have been presented in detail to understand the research and development activities happening around the world over the years. The study also delves into licensing and litigation battles which are restricting the commercial growth of the market. The report will also present a competitive landscape focusing on active players in the industry, growth strategies, strategic imperatives and detailed profiling of critical companies.

Get your analysis on 43 market data tables and 42 figures in 185 page up to date report and detailed TOC on CRISPR | Cas9 Market – Patent landscape report.

Global CRISPR-Cas9 mediated drug discovery and development market to contribute $2,403 million by 2025

In 2017, the global CRISPR-Cas9 mediated drug discovery and development market was estimated at $435 million. The market is expected to jump to $1,305 million by 2020 and further grow by a CAGR of 23.8 per cent over a period of eight years from 2017 to contribute $2,403 million by 2025. Drug discovery application segment held 35.6 per cent of CRISPR-Cas9 market share in 2017 which is expected to increase steadily over the forecasted period and comprise 45.2 per cent of the total market share in 2025.

USFDA announcement of CRISPR-Cas9 edited crops being treated as Non-GMOs

The application segment is expected to grow by four times of its market size of $156 million in 2017 to $609 million in 2025. CRISPR-Cas9 tools will play a multifarious role in agriculture by enabling the industry in editing crops to make them more nutritious, enhanced taste, disease resistant, and less susceptible to drought. Agriculture and plant breeding application segment is restricted in growth by several potential regulatory requirements and ethical apprehensions.

Top leading players and the geographic regions

The three leading players in the CRISPR field are Intellia Therapeutics, CRISPR Therapeutics, and Editas Medicine established by CRISPR pioneers has achieved billion-dollar market capitalization and are focused on the clinical as well as non-clinical applications of CRISPR-Cas9 technology. Large biotech companies and pharmaceuticals like Novartis, Vertex, Bayer AG have skin in the CRISPR game exploring novel techniques to evolve their drug discovery and development processes, and forming strategic alliances with crucial CRISPR technology companies to devise gene-based therapies for various genetic diseases.

The North American market has the maximum number of companies dealing with CRISPR-Cas9 products or services. About 64 per cent of the top companies with business related to CRISPR-Cas9 gene editing are in the U.S or Canada. The U.S. market is leading in the field regarding the number of companies involved in genome editing.

Novel treatments for single-gene disorders such as cystic fibrosis, haemophilia and sickle cell disease are being researched using Cas9 tools.

This technique is anticipated to be useful in the prevention and cure of complex conditions, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection. Research and Development investment in the technology is growing by leaps and bounds, the technology’s potential has been explored in newer areas of animal and disease model development, drug compound and target screening, and agriculture and nutritional health products.

Clinical therapy segment is the leading focus area of R&D with 482 patent applications

The Clinical therapy market is expected to contribute significantly to the overall CRISPR-Cas9 tools market. In 2017, the global CRISPR-Cas9 mediated clinical therapy market was estimated at $185 million. The market is expected to further grow by a CAGR of 19 per cent over a period of eight years from 2017 to contribute $744 million by 2025.Clinical therapy in APAC is expected to grow at a CAGR of 19.55 per cent for the period 2017 to 2025.

Region wise APAC is almost at par with North America in innovation activities with almost 44 percent of the fillings

The North American market lead the industry in 2017 with $504 million followed by Europe at $340 million and APAC closely behind at $325 million. The Chinese government is heavily committed to CRISPR research and has awarded more than 23 million yuan ($3.5 million) to 42 CRISPR projects. With an eight-year CAGR of 19.77 per cent, the North America market is predicted to continue dominating the global markets by 2025. APAC market is presumed to assume second position in the global markets with 3.96 per cent higher market share that European market in 2025. Rapid growth in the Rest of World (RoW) market is also expected.

A complex licensing model has sprouted around the pioneering IP portfolio.

All the CRISPR patent holders and institutes associated with them have set up companies to commercialize the patents by sublicensing them for therapeutic, agriculture and many other application areas to biotech firms, pharmaceuticals, agri-businesses etc. Caribou Biosciences, ERS Genomics, Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics are the spin offs associated with CRSIPR landscape. Not many large scale commercial assignees have actively participated in the early phases of the CRISPR–Cas patent landscape. The only large establishments making it to the top ten are Dow AgroSciences and DuPont Nutrition Science (now merged as DowDuPont), together holding 20 inventions in CRISPR-Cas9 applications in agriculture and animal biotechnology.

Get the most relevant, personalized intelligence for CRISPR-Cas9 market to make your company grow and succeed.

About Ahead Intelligence (AheadIntel) ™

Ahead Intelligence (AheadIntel) is a technology and patent research company providing premium, comprehensive technology research on different topics. We combine IP intelligence with business and market insights to give you the complete picture around a technology space. All our reports come with interactive dashboards that give you access to the patent data and allow you to dig deeper insights into the technology space.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
2. Horizon Discovery Presents an Educational Webinar on CRISPR-Cas9 Genome Engineering in Primary T cells
3. Plum Alley Closes $1.5M in Syndicate with Women and Men Investing in CRISPR-based Diagnostics Company
4. CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library
5. CRISPR system can promote antibiotic resistance
6. Shortening guide RNA markedly improves specificity of CRISPR-Cas nucleases
7. MediaPlanet and Dante Labs Team Up to Highlight the Role of Whole Genome Sequencing within Rare Diseases
8. to Host the Worlds First Hack the Genome Hackathon
9. Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine
10. BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree
11. House fly genome reveals expanded immune system
Post Your Comments:
(Date:4/17/2019)... , ... April 17, 2019 , ... USDM Life Sciences ... will deliver a presentation on solutions for Creating a Sustainable Global UDI Compliance Strategy ... the following insights:, , What device manufacturers did to comply ...
(Date:4/16/2019)... ... April 16, 2019 , ... ... search firms with over $2 billion in placement fees to recruiters and the ... employee onboarding platform, ExactHire. , This strategic relationship with ExactHire is the ...
(Date:4/16/2019)... ... April 16, 2019 , ... The International Society for ... 2019 ISPE Biopharmaceutical Manufacturing Conference , on 18–20 June and The ... of the most influential bio hubs, Boston, Massachusetts USA, these concurrent events bring ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... Konica ... today announced the formation of their inaugural Scientific Advisory Board. , ... that takes into account individual variability in genes, environment, and lifestyle to more ...
(Date:3/18/2019)... ... March 18, 2019 , ... For more than 15 years, ... that allow life science companies to easily comply with FDA 21 CFR Part 11 ... is a managed service delivering end-to-end GxP compliance from vendor audit through ongoing validation ...
(Date:3/14/2019)... ... March 14, 2019 , ... Open registration for the Case ... Spectrum of Case Management,” continues as CMSA makes plans to host the annual ... case management industry conference serving the educational and networking needs of case and ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... preclinical research organizations. It is a low code, GDPR/21 CFR Part 11-compliant ... innovative technology-driven automated data capture and seamless data and information management. ...
Breaking Biology Technology: